Literature DB >> 12751265

Clinical pharmacology of antifungal compounds.

Andreas H Groll1, Juan C Gea-Banacloche, Axel Glasmacher, Gudrun Just-Nuebling, Georg Maschmeyer, Thomas J Walsh.   

Abstract

Prompted by the worldwide surge in fungal infections, the past decade has witnessed a considerable expansion in antifungal drug research. New compounds have entered the clinical arena, and major progress has been made in defining paradigms of antifungal therapies. This article provides an up-to-date review on the clinical pharmacology, indications, and dosage recommendations of approved and currently investigational therapeutics for treatment of invasive fungal infections in adult and pediatric patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12751265     DOI: 10.1016/s0891-5520(02)00068-5

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  31 in total

Review 1.  Triazole antifungal agents in invasive fungal infections: a comparative review.

Authors:  Cornelia Lass-Flörl
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

Review 2.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

3.  Evaluating vaginitis. The importance of patient factors.

Authors:  Lisa L Willett; Robert M Centor
Journal:  J Gen Intern Med       Date:  2005-09       Impact factor: 5.128

Review 4.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

5.  Rapid susceptibility testing of medically important zygomycetes by XTT assay.

Authors:  Charalampos Antachopoulos; Joseph Meletiadis; Emmanuel Roilides; Tin Sein; Thomas J Walsh
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

6.  Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.

Authors:  D Andes; N Safdar; K Marchillo; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 7.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 8.  Newer antifungal agents.

Authors:  Walid Abuhammour; Eyassu Habte-Gaber
Journal:  Indian J Pediatr       Date:  2004-03       Impact factor: 1.967

Review 9.  Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.

Authors:  David Kaufman; Karen D Fairchild
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

10.  Management of neonatal candidiasis. Neonatal Candidiasis Study Group.

Authors:  J L Rowen; J M Tate
Journal:  Pediatr Infect Dis J       Date:  1998-11       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.